<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://bjo.bmj.com">
<title>BJO Online First</title>
<link>http://bjo.bmj.com</link>
<description>BJO RSS Feed -- Online First</description>
<prism:publicationName>British Journal of Ophthalmology</prism:publicationName>
<prism:issn>0007-1161</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301572v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301950v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301617v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300867v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301564v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301815v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301800v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301010v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301078v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301875v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301828v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301773v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301612v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301668v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301677v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301751v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300941v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301832v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301864v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301430v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301201v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301813v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301183v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300994v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301823v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301266v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300771v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300864v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301795v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301135v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301719v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301766v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301352v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301602v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300654v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301168v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301658v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300983v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300996v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301531v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301016v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300829v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301562v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301588v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301099v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301558v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300926v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301164v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300426v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301134v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301424v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301351v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301245v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301241v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301104v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300476v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjo.2010.201970v1?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/bjo.2010.199844v1?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.bjo.bmj.com/homepage/BJO_95x60.gif" />
</channel>
<image rdf:about="http://hwmaint.bjo.bmj.com/homepage/BJO_95x60.gif">
<title>British Journal of Ophthalmology</title>
<url>http://hwmaint.bjo.bmj.com/homepage/BJO_95x60.gif</url>
<link>http://bjo.bmj.com</link>
</image>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301572v1?rss=1">
<title><![CDATA[Calibrated needle for ophthalmic fine needle aspiration biopsy]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301572v1?rss=1</link>
<description><![CDATA[<p>In a great majority of cases, uveal tumours are diagnosed and treated based solely upon clinical examination and ancillary diagnostic studies such as ultrasonography and angiography.<cross-ref type="bib" refid="b1">1</cross-ref> In general, diagnostic fine needle aspiration biopsy (FNAB) is limited to situations presenting as a diagnostic dilemma such as differentiation between an amelanotic uveal melanoma and a metastatic uveal tumour.<cross-ref type="bib" refid="b2">2&ndash;5</cross-ref><cross-ref type="bib" refid="b3"></cross-ref><cross-ref type="bib" refid="b4"></cross-ref><cross-ref type="bib" refid="b5"></cross-ref> The other major indication for ophthalmic FNAB is for prognostication purposes of uveal melanoma being treated with radiation therapy.<cross-ref type="bib" refid="b6">6</cross-ref></p><p>Most ophthalmic surgeons have used available needles without customisation ranging in size from 22&nbsp;gauge (G) to 30G, with the 25G needle being the most commonly used.<cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b7">7</cross-ref> <cross-ref type="bib" refid="b8">8</cross-ref> There is evidence to suggest that the likelihood of insufficient samples may be greater with a thinner needle such as the 30G needle.<cross-ref type="bib" refid="b9">9</cross-ref> Moreover, currently used FNAB needles...]]></description>
<dc:creator><![CDATA[Pelayes, D. E., Zarate, J. O., Biscotti, C. V., Singh, A. D.]]></dc:creator>
<dc:date>2012-05-16T02:01:04-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301572</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301572</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Calibrated needle for ophthalmic fine needle aspiration biopsy]]></dc:title>
<prism:publicationDate>2012-05-16</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301950v1?rss=1">
<title><![CDATA[Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301950v1?rss=1</link>
<description><![CDATA[<p>I read with great excitement the article &lsquo;Therapeutic Potential of Valproic Acid for Retinitis Pigmentosa&rsquo;, by Clemson <I>et al</I>.<cross-ref type="bib" refid="b1">1</cross-ref> Patients who received oral valproic acid (VPA) were reported to have improvement in Goldmann visual field performance and best-corrected visual acuity (BCVA) measurements after a mean 4&nbsp;months of treatment. The current standard of care, vitamin A palmitate, has not been associated with any regression of disease or improvement in visual function in patients with retinitis pigmentosa (RP).<cross-ref type="bib" refid="b2">2</cross-ref> Rather, a subgroup of patients may experience a decreased rate of cone amplitude degradation, which has been used as a surrogate marker for visual function. Therefore, this seminal work has sparked off a multicentre, prospective, randomised, controlled phase II clinical trial with the aim to evaluate the safety and efficacy of oral VPA in patients with dominant forms of RP.<cross-ref type="bib" refid="b3">3</cross-ref> The study is currently enrolling patients, and the...]]></description>
<dc:creator><![CDATA[Sisk, R. A.]]></dc:creator>
<dc:date>2012-05-12T02:02:06-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301950</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301950</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa]]></dc:title>
<prism:publicationDate>2012-05-12</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301617v1?rss=1">
<title><![CDATA[Prominent corneal nerves: a novel sign of lipoid proteinosis]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301617v1?rss=1</link>
<description><![CDATA[<sec><st>Aim</st><p>Detailed longitudinal evaluation of corneal and other ophthalmological features of patients with lipoid proteinosis (LP).</p></sec><sec><st>Methods</st><p>Ophthalmological examinations, chart review, ultrasound biomicroscopy, corneal confocal microscopic examinations with Nidek confoScan 4 and direct sequencing of the extracellular matrix protein 1 gene in individuals from three consanguineous Saudi families with LP.</p></sec><sec><st>Results</st><p>Seven individuals affected with LP (four female and three male subjects) were evaluated together with nine unaffected parents and siblings. All affected individuals had homozygous mutations in extracellular matrix protein 1. Four patients were examined frequently (every 6&nbsp;months) beginning in infancy and early childhood. Globe and vision were normal in all individuals, and moniliform blepharosis always appeared after the age of 4&nbsp;years. Prominent corneal nerves were detected in all patients regardless of age and were more apparent in patients with more severe genetic mutations. Conversely, the severity of moniliform blepharosis seemed age-dependent rather than genotype-related.</p></sec><sec><st>Conclusion</st><p>Prominent corneal nerves can be helpful in the early diagnosis of LP and should be added to the list of LP ophthalmological diagnostic features.</p></sec>]]></description>
<dc:creator><![CDATA[Al-Faky, Y. H., Bosley, T. M., Al-Turki, T., Salih, M. A. M., Abu-Amero, K. K., Alsuhaibani, A. H.]]></dc:creator>
<dc:date>2012-05-12T02:02:06-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301617</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301617</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Public health]]></dc:subject>
<dc:title><![CDATA[Prominent corneal nerves: a novel sign of lipoid proteinosis]]></dc:title>
<prism:publicationDate>2012-05-12</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300867v1?rss=1">
<title><![CDATA[Cyclodeviation of the retinal vascular arcades: an accessory sign of ocular torsion]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300867v1?rss=1</link>
<description><![CDATA[<p>Assessment of ocular torsion via fundus examination is an important tool for diagnosis and management of cyclorotational disorders. The widely used disc&ndash;macula relationship for quantification of ocular torsion possesses inherent limitations, which restricts its use in some clinical scenarios. An accessory technique of fundus examination for assessing torsion is hereby proposed using vascular cues. Retinal blood vessels share common guidance signals with ganglion cell axons and are now recognised to follow retinal axonal pathways. Identification of the axis of the retinal vascular arcades can serve as a direct and accessory means to provide additional pertinent information regarding ocular cyclorotations.</p>]]></description>
<dc:creator><![CDATA[Parsa, C. F., Kumar, A. B.]]></dc:creator>
<dc:date>2012-05-12T02:02:06-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300867</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300867</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Cyclodeviation of the retinal vascular arcades: an accessory sign of ocular torsion]]></dc:title>
<prism:publicationDate>2012-05-12</prism:publicationDate>
<prism:section>Innovations</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301564v1?rss=1">
<title><![CDATA[Epimacular membrane secondary to an optic nerve head lesion]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301564v1?rss=1</link>
<description><![CDATA[<p>A 57-year-old woman presented to us with blurred vision in her right eye for approximately a year. She gave no history of any systemic illness, ocular surgery or trauma. Best-corrected visual acuity (BCVA) was 20/70 in the right eye and 20/20 in the left. The anterior segments were unremarkable in both eyes. Fundus examination of right eye showed a tuft of anomalous papillary vessels with adjoining epimacular membrane (EMM) (<cross-ref type="fig" refid="fig1">figure 1A</cross-ref>). Fundus of the left eye was normal. There was no evidence of posterior vitreous detachment or any coexistent retinal pathology in either eye. Fluorescein angiography of the right eye showed delayed filling of the papillary aneurysms with characteristic erythrocyte&ndash;plasma interface, as well as distortion and leakage of parafoveal capillaries (<cross-ref type="fig" refid="fig1">figure 1B</cross-ref>). Optical coherence tomography (OCT; Stratus OCT; Carl Zeiss Meditec, Dublin, California, USA) of the right eye confirmed the EMM, central foveal thickness was 556&nbsp;&mu;m...]]></description>
<dc:creator><![CDATA[Shukla, D., Sharan, A.]]></dc:creator>
<dc:date>2012-05-11T02:01:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301564</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301564</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Public health, Ophthalmologic surgical procedures, Vitreous]]></dc:subject>
<dc:title><![CDATA[Epimacular membrane secondary to an optic nerve head lesion]]></dc:title>
<prism:publicationDate>2012-05-11</prism:publicationDate>
<prism:section>Education</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301815v1?rss=1">
<title><![CDATA[Expression of prostaglandin F receptor in scleral and subconjunctival tissue]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301815v1?rss=1</link>
<description><![CDATA[<p>Prostaglandin F2&alpha; (PGF<SUB>2&alpha;</SUB>) analogues eye drops are regarded as a first choice for the treatment of glaucoma. The hypotensive action of PGF<SUB>2&alpha;</SUB> analogues is thought to be attributed to an increase in uveoscleral outflow.<cross-ref type="bib" refid="b1">1</cross-ref> However, the underlying mechanisms have yet to be well defined. The purpose of this present study was to examine prostaglandin F receptor (FP) localisation in ocular tissue.</p><p>All experiments were conducted in accordance with the principles set forth in the Declaration of Helsinki. The expression of FP was examined by X-gal staining in ocular tissues of FP knockout mice carrying the &beta;-galactosidase gene at the FP loci (<I>Ptgfr<sup>&ndash;/&ndash;</sup></I> mice)<cross-ref type="bib" refid="b2">2</cross-ref> and reverse transcription PCR of human conjuncitival and scleral fibroblasts (see supplementary methods, published online only).</p><p>First, FP localisation was examined using <I>Ptgfr<sup>&ndash;/&ndash;</sup></I> mice in which the &beta;-galactosidase gene was &lsquo;knocked-in&rsquo; at the FP gene. In the <I>Ptgfr<sup>&ndash;/&ndash;</sup></I> mice, X-gal staining of ocular tissue revealed...]]></description>
<dc:creator><![CDATA[Imai, K., Ueta, M., Mori, K., Ueno, M., Ikeda, Y., Oga, T., Yokoi, N., Shinomiya, K., Narumiya, S., Kinoshita, S.]]></dc:creator>
<dc:date>2012-05-11T02:01:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301815</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301815</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Expression of prostaglandin F receptor in scleral and subconjunctival tissue]]></dc:title>
<prism:publicationDate>2012-05-11</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301800v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301800v1?rss=1</link>
<description><![CDATA[<p>We thank Leach <I>et al</I> for their interest in our recent publication &lsquo;Comparative gene expression profiling of human umbilical vein endothelial cells (HUVEC) and ocular vascular endothelial cells.&rsquo;</p><p>Our experiments are based on monolayers of endothelial cells (ECs) grown under similar conditions for comparison. The results show significant differences between retinal and choroidal microvascular ECs and HUVEC. This is not surprising as particular diseases have particular predilection for specific vascular beds even within the same organ. The investigation of proliferation and IGF signalling in the microvascular ECs was confirmatory to our microarray studies. It was not directed at testing the potential of IGF to act as a costimulatory factor for somatic cell reprogramming.<cross-ref type="bib" refid="b1">1</cross-ref> It was unnecessary to undertake further evaluation of HUVEC specifically.</p><p>We are of the opinion that postmortem artefact, including cessation of circulation, cannot be postulated as an explanation for the increased expression of pro-inflammatory genes in the...]]></description>
<dc:creator><![CDATA[Browning, A. C., Stewart, E. A., Amoaku, W. M.]]></dc:creator>
<dc:date>2012-05-08T02:01:46-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301800</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301800</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2012-05-08</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301010v1?rss=1">
<title><![CDATA[Retinal nerve fibre layer thickness in school-aged prematurely-born children compared to children born at term]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301010v1?rss=1</link>
<description><![CDATA[<sec><st>Aim</st><p>To investigate the retinal nerve fibre layer (RNFL) with optical coherent tomography (OCT) in prematurely-born children.</p></sec><sec><st>Methods</st><p>62 children born with a gestational age of &le;32&nbsp;weeks, and a control group of 54 children born at term with normal birth weight (BW) were included in the study. 28 of the preterm children had retinopathy of prematurity (ROP) in the neonatal period; eight of them had severe ROP (stages 3&ndash;4). RNFL thickness was measured with Stratus OCT 3. Mean age at examination was 8.6&nbsp;years in the preterm children and 10.1&nbsp;years in the control group.</p></sec><sec><st>Results</st><p>There was a significant difference between the children born preterm and those born at term, regarding RNFL thickness in the superior (right eye (RE), p=0.043; left eye (LE), p=0.048) and the nasal quadrants (RE, p=0.006; LE, p&lt;0.001), as well as average RNFL thickness (RE, p=0.016; LE, p=0.029). This difference was caused by the thinner RNFL in children with previous severe ROP (stages 3 and 4). Within the preterm group, the average RNFL thickness increased with larger BW (RE, p=0.050; LE, p=0.028), but there was no correlation with gestational age at birth.</p></sec><sec><st>Conclusion</st><p>The RNFL was reduced in prematurely-born children with severe ROP when compared to children born at term. It is hypothesised that severe retinopathy as well as ablation of the retina with laser treatment or cryotherapy may affect the axons of the ganglion cells and thus reduce RNFL thickness. Prematurely-born children with low BW had a thinner RNFL, suggesting a negative effect of low birth weight on neural development.</p></sec>]]></description>
<dc:creator><![CDATA[Akerblom, H., Holmstrom, G., Eriksson, U., Larsson, E.]]></dc:creator>
<dc:date>2012-05-08T02:01:47-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301010</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301010</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Retina]]></dc:subject>
<dc:title><![CDATA[Retinal nerve fibre layer thickness in school-aged prematurely-born children compared to children born at term]]></dc:title>
<prism:publicationDate>2012-05-08</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301078v1?rss=1">
<title><![CDATA[Short term LASIK outcomes using the Technolas 217C excimer laser and Hansatome microkeratome in 46 708 eyes treated between 1998 and 2001]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301078v1?rss=1</link>
<description><![CDATA[<sec><st>Purpose</st><p>To report the outcomes of a high-volume, multi-surgeon, multicentre LASIK corporation between 1998 and 2001.</p></sec><sec><st>Methods</st><p>46 708 eyes of 24 138 consecutive patients with myopic astigmatism had undergone LASIK using the Bausch &amp; Lomb Technolas 217C excimer laser and Hansatome microkeratome. The study included 38 surgeons operating at 11 surgical centres. 31 surgeons underwent standardised training regardless of previous experience, which included didactic, observership and proctorship components. Mean attempted spherical equivalent refraction correction was &ndash;4.02&plusmn;1.93 D (range &ndash;0.50 to &ndash;12.00 D). Mean attempted cylinder correction was 0.78&plusmn;0.69 D (range 0.00 to 3.50 D). Median follow-up was 3&nbsp;months.</p></sec><sec><st>Results</st><p>Postoperative data with at least 1&nbsp;month follow-up was available in 35 360 eyes (76%) of 18 195 patients. Predictability: mean deviation from intended spherical equivalent refraction correction was &ndash;0.21&plusmn;0.47 D with 81% of eyes within &plusmn;0.50 D and 95% of eyes within &plusmn;1.00 D. Efficacy: uncorrected distance visual acuity was 20/20 in 71% of eyes and 20/40 in 95% of eyes. Safety: two or more lines of corrected distance visual acuity were lost in 0.57% of eyes. Postoperative corrected distance visual acuity was worse than 20/40 in 0.029% of eyes.</p></sec><sec><st>Conclusions</st><p>The short-term results of a high-volume, multi-surgeon LASIK Corporation were comparable with those reported in the Food and Drug Administration clinical trials during the same period.</p></sec>]]></description>
<dc:creator><![CDATA[Reinstein, D. Z., Threlfall, W. B., Cook, R., Cremonesi, E., Sutton, H. F., Archer, T. J., Gobbe, M.]]></dc:creator>
<dc:date>2012-05-08T02:01:47-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301078</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301078</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Ophthalmologic surgical procedures, Optic nerve, Optics and refraction]]></dc:subject>
<dc:title><![CDATA[Short term LASIK outcomes using the Technolas 217C excimer laser and Hansatome microkeratome in 46 708 eyes treated between 1998 and 2001]]></dc:title>
<prism:publicationDate>2012-05-08</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301875v1?rss=1">
<title><![CDATA[Mooren's ulcer or peripheral ulcerative keratitis]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301875v1?rss=1</link>
<description><![CDATA[<p>Mathur <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> published an interesting article regarding Mooren's ulcer in children. However, there are a few reservations regarding the diagnosis. Peripheral corneal ulceration/keratitis can be a feature of Mooren's ulcer, Terrien's marginal degeneration, peripheral ulcers associated with rheumatoid arthritis or Wegener's granulomatosis and vitamin A deficiency<cross-ref type="bib" refid="b2">2</cross-ref> in patients with malabsorption/malnutrition syndromes (especially relevant in developing countries).</p><p>Mathur <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> write about the diagnosis &lsquo;absence of any systemic disease, also confirmed by relevant systemic investigations such as a normal complete blood count, a normal erythrocyte sedimentation rate and negative markers of immunological disorders that can result in a similar clinical picture&rsquo;. Following are a few points regarding their statement. First, the authors have not mentioned what specific investigations were performed. It is not clear whether serum rheumatoid factor, antinuclear antibodies, cytoplasmic antineutrophil cytoplasmic antibodies and serine proteinase 3 antibodies were performed or not to rule...]]></description>
<dc:creator><![CDATA[Shoaib, K. K.]]></dc:creator>
<dc:date>2012-05-03T02:01:19-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301875</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301875</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Mooren's ulcer or peripheral ulcerative keratitis]]></dc:title>
<prism:publicationDate>2012-05-03</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301828v1?rss=1">
<title><![CDATA[The changing face of corneal graft rejection]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301828v1?rss=1</link>
<description><![CDATA[<p>The cornea is the most commonly transplanted human tissue. It is estimated that globally over 65 000 corneal transplants are being performed each year.<cross-ref type="bib" refid="b1">1</cross-ref> Over 16 000 corneal transplants were performed in the UK alone since 2005.<cross-ref type="bib" refid="b2">2</cross-ref></p><p>The cornea is largely considered to be an immune privileged site. There are several attributes that contribute to this notion such as the compact architecture of the corneal stroma, which is believed to retard migration of immune cells; the physiological blood&ndash;aqueous barrier that prevents any immunogenic mediators and cells entering the ocular tissue;<cross-ref type="bib" refid="b3">3</cross-ref> the relative lack of lymphatics and blood vessels; the presence of unique factors within the ocular fluids like transforming growth factor-&beta;, calcitonin gene-related peptide, melanocyte stimulating hormone and vasoactive intestinal peptide and cortisol binding globulin,<cross-ref type="bib" refid="b4">4&ndash;6</cross-ref><cross-ref type="bib" refid="b5"></cross-ref><cross-ref type="bib" refid="b6"></cross-ref> which contribute to immune modulation/anterior chamber associate immune deviation wherein antigen introduced in to the anterior...]]></description>
<dc:creator><![CDATA[Faraj, L. A., Hashmani, K., Khatib, T., Al-Aqaba, M., Dua, H. S.]]></dc:creator>
<dc:date>2012-04-29T02:02:35-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301828</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301828</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Ophthalmologic surgical procedures, Cornea, Ocular surface]]></dc:subject>
<dc:title><![CDATA[The changing face of corneal graft rejection]]></dc:title>
<prism:publicationDate>2012-04-29</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301773v1?rss=1">
<title><![CDATA[Re: 'Long-term surgical outcomes of porous polyethylene orbital implants: a review of 314 cases']]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301773v1?rss=1</link>
<description><![CDATA[<p>The debate between evisceration and enucleation is well documented in literature. Minimal orbital dissection required in evisceration has made it a more preferable choice except for certain absolute indications for enucleation. Cosmetic appearance, motility, implant exposure and extrusion are the most frequently discussed complications between these two procedures. In a recent study by Jung <I>et al</I>,<cross-ref type="bib" refid="b1">1</cross-ref> the fornix contraction was noted in 13.9% cases of enucleation (with unwrapped porous polyethylene) versus 3% cases of evisceration (with porous polyethylene placed in scleral shell). We would like to discuss the risk and probable causes for fornix contraction after the enucleation/evisceration. Although the contraction of fornix has been previously observed in a few studies, discussion is lacking in current literature.</p><p>In addition to the study by Jung <I>et al</I>,<cross-ref type="bib" refid="b1">1</cross-ref> another study Shoamanesh <I>et al</I><cross-ref type="bib" refid="b2">2</cross-ref> noted three cases of fornix contraction in enucleation with porous polyethylene implant. Nakra <I>et...]]></description>
<dc:creator><![CDATA[Kamal, S., Bodh, S. A., Goel, R., Kumar, S.]]></dc:creator>
<dc:date>2012-04-29T02:02:35-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301773</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301773</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Re: 'Long-term surgical outcomes of porous polyethylene orbital implants: a review of 314 cases']]></dc:title>
<prism:publicationDate>2012-04-29</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301612v1?rss=1">
<title><![CDATA[Foveal avascular zone and foveal pit formation after preterm birth]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301612v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Vascularisation of the macula takes place between 24 and 27&nbsp;weeks post-conception. Preterm birth may affect the formation of the foveal avascular zone (FAZ) and foveal depression, and displacement of inner retinal layers away from the incipient fovea.</p></sec><sec><st>Objective</st><p>To examine whether vascular abnormalities accompany an inner retinal abnormality, and whether they are coincident.</p></sec><sec><st>Methods</st><p>High-density spectral domain optical coherence tomography volume scans were obtained from 24 preterm children and 34 full-term controls (5&ndash;16&nbsp;years). Matlab programs were used to quantify total retinal thickness, thickness of individual retinal layers and metrics of foveal morphology. Summed voxel projections for the ganglion cell layer&ndash;inner nuclear layer were used to identify the FAZ.</p></sec><sec><st>Results</st><p>Preterm children had significantly smaller FAZ diameters than controls (p&lt;0.0001). The foveal pits of preterm children were significantly shallower and less steep (p&lt;0.0001) and total retinal thickness at the fovea was significantly increased (p&lt;0.0001) compared to controls. The ganglion cell layer&ndash;inner plexiform layer and outer nuclear layer were significantly (p&le;0.0001) thicker in preterm children than in controls.</p></sec><sec><st>Conclusions</st><p>Preterm birth results in abnormal foveal vascularisation, a failure of the inner retinal neurons to migrate away from the fovea, and an elevated outer nuclear layer ratio. The spatial coincidence of inner retinal and vascular abnormalities in preterm children supports the hypothesis that aspects of foveal development are interdependent.</p></sec>]]></description>
<dc:creator><![CDATA[Yanni, S. E., Wang, J., Chan, M., Carroll, J., Farsiu, S., Leffler, J. N., Spencer, R., Birch, E. E.]]></dc:creator>
<dc:date>2012-04-29T02:02:34-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301612</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301612</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Paediatrics]]></dc:subject>
<dc:title><![CDATA[Foveal avascular zone and foveal pit formation after preterm birth]]></dc:title>
<prism:publicationDate>2012-04-29</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301668v1?rss=1">
<title><![CDATA[Allogeneic serum eye drops: time these became the norm?]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301668v1?rss=1</link>
<description><![CDATA[<p>Serum eye drops contain growth and neurotrophic factors, fibronectin and vitamin A that promote corneal epithelialisation and nerve healing and are a well-established treatment for ocular surface disorders.<cross-ref type="bib" refid="b1">1</cross-ref> Though normally derived from autologous blood, not all patients can be donors for reasons such as infancy, poor venous access and comorbidities. Also, autologous serum from some patients could potentially contain concentrations of drugs,<cross-ref type="bib" refid="b2">2</cross-ref> or possibly, inflammatory mediators, harmful to the eye. Allogeneic drops are an alternative in such circumstances.</p><p>Complex mechanisms make the eye an immunologically privileged site.<cross-ref type="bib" refid="b3">3</cross-ref> Cornea and conjunctiva bear ABO antigens and some HLA.<cross-ref type="bib" refid="b4">4</cross-ref> Serum contains antibodies and complement. Nevertheless, successful treatment with ABO-unselected allogeneic serum is reported.<cross-ref type="bib" refid="b5">5</cross-ref> <cross-ref type="bib" refid="b6">6</cross-ref> Furthermore, ABO-matching is unnecessary for corneal or conjunctival transplants and, other than haemolysis, minor ABO-mismatched, plasma-containing, platelet transfusions pose little risk of type II hypersensitivity reactions. There are...]]></description>
<dc:creator><![CDATA[Badami, K. G., McKellar, M.]]></dc:creator>
<dc:date>2012-04-26T02:03:51-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301668</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301668</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Allogeneic serum eye drops: time these became the norm?]]></dc:title>
<prism:publicationDate>2012-04-26</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301677v1?rss=1">
<title><![CDATA[Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301677v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Retinal endothelial cells are crucially involved in the genesis of diabetic retinopathy which is treated with vascular endothelial growth factor (VEGF) inhibitors. Of these, ranibizumab can completely restore VEGF-induced effects on immortalised bovine retinal endothelial cells (iBREC). In most experiments supporting diabetic retinopathy therapy with bevacizumab, only non-retinal EC or retinal pigment epithelial cells have been used. Also, bevacizumab but not ranibizumab can accumulate in retinal pigment epithelial cells.</p></sec><sec><st>Objective</st><p>To investigate the effects of bevacizumab on VEGF-induced changes of iBREC properties and potential uptake and accumulation of both inhibitors.</p></sec><sec><st>Methods</st><p>Uptake of VEGF inhibitors by iBREC with or without pretreatment with VEGF<SUB>165</SUB> was visualised by immunofluorescence staining and western blot analyses. Measured transendothelial resistance (TER) of iBREC (&plusmn;VEGF<SUB>165</SUB>) showed effects on permeability, indicated also by the western blot-determined tight junction protein claudin-1. The influence of bevacizumab on proliferation and migration of iBREC was studied in the presence and absence of VEGF<SUB>165</SUB>.</p></sec><sec><st>Results</st><p>Bevacizumab strongly inhibited VEGF-stimulated and basal migration, but was less efficient than ranibizumab in inhibiting VEGF-induced proliferation or restoring the VEGF-induced decrease of TER and claudin-1. This ability was completely lost after storage of bevacizumab for 4&nbsp;weeks at 4&deg;C. Ranibizumab and bevacizumab were detectable in whole cell extracts after treatment for at least 1&nbsp;h; bevacizumab accumulated during prolonged treatment. Ranibizumab was found in the membrane/organelle fraction, whereas bevacizumab was associated with the cytoskeleton.</p></sec><sec><st>Conclusion</st><p>Both inhibitors had similar effects on retinal endothelial cells; however, some differences were recognised. Although barrier properties were not affected by internalised bevacizumab in vitro, potential adverse effects due to accumulation after repetitive intravitreal injections remain to be investigated.</p></sec>]]></description>
<dc:creator><![CDATA[Deissler, H. L., Deissler, H., Lang, G. E.]]></dc:creator>
<dc:date>2012-04-26T02:03:51-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301677</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301677</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Retina, Unlocked]]></dc:subject>
<dc:title><![CDATA[Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences]]></dc:title>
<prism:publicationDate>2012-04-26</prism:publicationDate>
<prism:section>Original articles - Laboratory science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301751v1?rss=1">
<title><![CDATA[Efficacy of a remote based computerised visual acuity measurement]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301751v1?rss=1</link>
<description><![CDATA[<sec><st>Aim</st><p>To determine the efficacy of a remotely operated computer-based logarithmic (logMAR) visual acuity chart.</p></sec><sec><st>Methods</st><p>Visual acuity was tested using a laptop or computer-based logMAR chart (COMPlog) for all subjects by two different methods. The methods differed by the physical presence and absence (remote) of an optometrist and in the mode of instructions provided. Remote access was obtained through the internet, using Teamviewer software to control the system linked to COMPlog and instructions were provided by telephone. The order of measurements and the eye to be tested was randomised. logMAR visual acuity and time taken were recorded. A questionnaire was used to assess the participant's feedback.</p></sec><sec><st>Results</st><p>Intraclass correlation for visual acuity between the two methods (&alpha;=0.964, 95% CI 0.937 to 0.979). There was no statistically significant difference (p=0.648) in the median visual acuity measurement between the two methods (median difference 0.00, IQR 0.20 logMAR). The time taken between the two methods was not statistically significant (p=0.457). There was no significant difference in the responses to the questionnaire between the study methods (p=0.119).</p></sec><sec><st>Conclusions</st><p>Tele (remotely controlled) visual acuity measurement is as reliable as that measured with the physical presence of an optometrist.</p></sec>]]></description>
<dc:creator><![CDATA[Srinivasan, K., Ramesh, S. V., Babu, N., Sanker, N., Ray, A., Karuna, S. M.]]></dc:creator>
<dc:date>2012-04-26T02:03:50-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301751</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301751</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Efficacy of a remote based computerised visual acuity measurement]]></dc:title>
<prism:publicationDate>2012-04-26</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300941v1?rss=1">
<title><![CDATA[Endothelial keratoplasty in children: surgical challenges and early outcomes]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300941v1?rss=1</link>
<description><![CDATA[<sec><st>Introduction</st><p>A significant proportion of paediatric keratoplasties are performed for endothelial dysfunction due to failed graft, congenital hereditary endothelial dystrophy<cross-ref type="bib" refid="b1">1</cross-ref> and pseudophakic corneal oedema. Descemet's stripping endothelial keratoplasty (DSEK) is an evolving procedure for isolated endothelial dysfunction with encouraging results in adults. The application and outcome of this procedure in the paediatric population has not been well studied with few reports being published so far.<cross-ref type="bib" refid="b2">2&ndash;5</cross-ref><cross-ref type="bib" refid="b3"></cross-ref><cross-ref type="bib" refid="b4"></cross-ref><cross-ref type="bib" refid="b5"></cross-ref></p><p>This study reports the indications, surgical technique and early outcomes of DSEK in children &lt;14&nbsp;years of age.</p></sec><sec><st>Methods</st><p>All children who underwent DSEK at our centre between January 2008 and January 2010 were included. Under general anaesthesia, an appropriate sized superior or temporal fornix based conjunctival flap was reflected and a 4&ndash;5&nbsp;mm long, self-sealing scleral tunnel was made. The Descemet's membrane was scored using a reverse Sinskey hook and then stripped (except in cases of failed grafts). An anterior...]]></description>
<dc:creator><![CDATA[Ramappa, M., Ashar, J., Vaddavalli, P. K., Chaurasia, S., Murthy, S. I.]]></dc:creator>
<dc:date>2012-04-26T02:03:51-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300941</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300941</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Endothelial keratoplasty in children: surgical challenges and early outcomes]]></dc:title>
<prism:publicationDate>2012-04-26</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301832v1?rss=1">
<title><![CDATA[How much of invasive clinical research is still ethically justified?]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301832v1?rss=1</link>
<description><![CDATA[<p>Two research studies published in <I>BJO</I><cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> were based on invasive procedures. The previous similar studies were conducted in China and related ethical concerns were reported.<cross-ref type="bib" refid="b3">3</cross-ref> <cross-ref type="bib" refid="b4">4</cross-ref> Although the discussed studies were conducted in Europe, they raise similar concerns. Both studies were conducted by the same research group and were based on the same studied group of patients: 18 patients with normal-tension glaucoma who underwent cisternography with lumbar puncture (LP). Control group constituted age- and gender-matched individuals without known intracranial or optic nerve disease who underwent CT scanning for maxillary and ethmoid sinus disease.</p><p>It should be pointed that a great deal of literature has shown little or no foundation for the idea that low cerebrospinal fluid pressure is related to optic neuropathy.<cross-ref type="bib" refid="b5">5</cross-ref> In 2008, Louis R Pasquale wrote: &lsquo;<I>Yet it is probably not feasible or ethical to subject neurologically asymptomatic...]]></description>
<dc:creator><![CDATA[Grzybowski, A.]]></dc:creator>
<dc:date>2012-04-25T02:01:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301832</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301832</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[How much of invasive clinical research is still ethically justified?]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301864v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301864v1?rss=1</link>
<description><![CDATA[<p>We thank Dr Gryzbowski for his comments.<cross-ref type="bib" refid="b1">1</cross-ref> Indeed, we agree that there is little or no foundation for the theory that low cerebrospinal fluid (CSF) pressure is related to the optic neuropathy of the so-called low-tension glaucoma and lumbar punctures are not helpful in this setting; however, our research relates to the effects of disordered circulation of CSF as well as to CSF content and not to CSF pressure.<cross-ref type="bib" refid="b2">2&ndash;4</cross-ref><cross-ref type="bib" refid="b3"></cross-ref><cross-ref type="bib" refid="b4"></cross-ref> It seems that Dr Grzybowski misunderstood the content of our study. Additionally, Dr Grzybowski is concerned that we have not appropriately informed our patients about the risks of a lumbar puncture. In fact, all patients were informed in detail about the potential benefits versus risks of a lumbar puncture. In addition, the study was approved by our ethics committee. We agree with Dr Grzybowski that one must weigh the risks and benefits of...]]></description>
<dc:creator><![CDATA[Killer, H. E., Miller, N. R., Flammer, J., Jaggi, G. P., Remonda, L.]]></dc:creator>
<dc:date>2012-04-25T02:01:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301864</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301864</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301430v1?rss=1">
<title><![CDATA[Uncorrected refractive error in older British adults: the EPIC-Norfolk Eye Study]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301430v1?rss=1</link>
<description><![CDATA[<sec><st>Aim</st><p>To investigate the prevalence of, and demographic associations with, uncorrected refractive error (URE) in an older British population.</p></sec><sec><st>Methods</st><p>Data from 4428 participants, aged 48&ndash;89&nbsp;years, who attended an eye examination in the third health check of the European Prospective Investigation into Cancer-Norfolk study and had also undergone an ophthalmic examination were assessed. URE was defined as &ge;1 line improvement of visual acuity with pinhole-correction in the better eye in participants with LogMar presenting visual acuity (PVA) &lt;0.3 (PVA &lt;6/12). Refractive error was measured using an autorefractor without cycloplegia. Myopia was defined as spherical equivalent &le;&ndash;0.5 dioptre, and hypermetropia &ge;0.5 dioptre.</p></sec><sec><st>Results</st><p>Adjusted to the 2010 midyear British population, the prevalence of URE in this Norfolk population was 1.9% (95% CI 0.6% to 3.1%). Lower self-rated distance vision was correlated with higher prevalence of URE (p<SUB>trend</SUB>&lt;0.001). In a multivariate logistic regression model adjusting for age, gender, retirement status, educational level and social class, independent significant associations with URE were increasing age (p<SUB>trend</SUB>&lt;0.001) and having hypermetropic or myopic refractive error. Wearing distance spectacles was inversely associated with URE (OR 0.34, 95% CI 0.21 to 0.55, p&lt;0.001). There were 3063 people (69.2%) who wore spectacles/contact lenses for distance vision. Spectacle wear differed according to type of refractive error (p&lt;0.001), and use rose with increasing severity of refractive error (p<SUB>trend</SUB>&lt;0.001).</p></sec><sec><st>Conclusion</st><p>Although refractive error is common, the prevalence of URE was found to be low in this population reflecting a low prevalence of PVA&lt;0.3.</p></sec>]]></description>
<dc:creator><![CDATA[Sherwin, J. C., Khawaja, A. P., Broadway, D., Luben, R., Hayat, S., Dalzell, N., Wareham, N. J., Khaw, K.-T., Foster, P. J.]]></dc:creator>
<dc:date>2012-04-25T02:01:32-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301430</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301430</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Optic nerve, Optics and refraction]]></dc:subject>
<dc:title><![CDATA[Uncorrected refractive error in older British adults: the EPIC-Norfolk Eye Study]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301201v1?rss=1">
<title><![CDATA[Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301201v1?rss=1</link>
<description><![CDATA[<sec><st>Purpose</st><p>To assess the effect of ranibizumab treatment for neovascular age-related macular degeneration (nvAMD) on patients' preferences and vision-related quality of life (VRQoL) in a routine clinical setting.</p></sec><sec><st>Methods</st><p>55 treatment na&iuml;ve patients were examined before and after the initial upload of three monthly injections of 0.5&nbsp;mg ranibizumab. VRQoL was assessed using a Rasch-adjusted NEI-VFQ-25. Time trade-off (TTO), standard gamble, a visual analogue scale and the European Quality of Life Questionnaire (EQ-5D) were used to calculate utilities, and multiple logistic regression models were conducted to determine independent factors associated with utilities.</p></sec><sec><st>Results</st><p>Mean&plusmn;SD age was 75&plusmn;7&nbsp;years, and 40 patients (73%) were female. Mean&plusmn;SD best-corrected visual acuity of the treated eye increased from 20/80 at baseline (logMAR 0.60&plusmn;0.35) to 20/63 (logMAR 0.52&plusmn;0.36; p=0.020) at follow-up after three injections. Utility score increases ranged from 2&nbsp;utils (standard gamble anchored for death) up to 6.6&nbsp;utils (EQ-5D German TTO, p=0.023) and visual functioning improved (Rasch adjusted composite NEI-VFQ score 50&plusmn;21 to 54&plusmn;21, p=0.042). Whether the worse or better eye was treated was not significantly associated with improvements in utility or VRQoL, whereas VA improvement in the treated eye was associated with an increase in utility (TTO, p=0.020).</p></sec><sec><st>Conclusions</st><p>TTO performed best in this sample of elderly nvAMD patients undergoing anti-VEGF therapy. Better or worse eye treatment was not associated with a change in reported utilities or visual functioning in patients with newly diagnosed nvAMD. Directly elicited, vision-specific utilities gained with TTO seem to be sensitive to a change in vision status.</p></sec>]]></description>
<dc:creator><![CDATA[Finger, R., Hoffmann, A. E., Fenwick, E. K., Wolf, A., Kampik, A., Kernt, M., Neubauer, A. S., Hirneiss, C.]]></dc:creator>
<dc:date>2012-04-25T02:01:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301201</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301201</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Public health, Retina]]></dc:subject>
<dc:title><![CDATA[Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301813v1?rss=1">
<title><![CDATA[Diabetic CVI figures for England and Wales (2007-2009)]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301813v1?rss=1</link>
<description><![CDATA[<p>The views expressed in this paper are the views of the authors and not necessarily any funding body or the Department of Health. The data captured by the certificate of vision impairment (CVI) are Department of Health copyright and this work was made possible by collaboration with the Royal College of Ophthalmologists.</p><p>We read the paper by Minassian <I>et al</I> with great interest and thought that figures we have derived from the Certifications Office, London, on the incidence of new certifications for diabetic eye disease would be a useful resource alongside the prevalence figures provided.<cross-ref type="bib" refid="b1">1</cross-ref> Certification figures are very much of interest at present since an indicator for preventable sight loss has very recently been included in the Public Health Outcomes Framework.<cross-ref type="bib" refid="b2">2</cross-ref> In order for an individual to be registered as sight impaired in the UK, they must be first be certified as visually impaired by a...]]></description>
<dc:creator><![CDATA[Bunce, C., Stratton, I. M., Cohen, S.]]></dc:creator>
<dc:date>2012-04-21T02:00:58-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301813</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301813</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Diabetic CVI figures for England and Wales (2007-2009)]]></dc:title>
<prism:publicationDate>2012-04-21</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301183v1?rss=1">
<title><![CDATA[Living with nystagmus: a qualitative study]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301183v1?rss=1</link>
<description><![CDATA[<sec><st>Background/aims</st><p>To identify aspects of daily living affected by nystagmus.</p></sec><sec><st>Methods</st><p>Semistructured interviews were conducted at the University of Leicester, UK with participants with acquired and infantile nystagmus. In total 21, participants were purposively sampled and recruited. Transcript analysis was conducted using constant comparative technique, based upon the grounded theory, to identify specific areas of living affected by nystagmus.</p></sec><sec><st>Results</st><p>Analysis identified six domains that were adversely affected by nystagmus; visual function, restriction of movement, standing out/not fitting in, feelings about the inner self, negativity about the future and relationships. Cosmetic appearance of nystagmus, including others' avoidant response to this, was described (n=18), as was others' failure to recognise what it is like to have nystagmus (n=18). Driving issues were frequently raised (n=19) and restrictions in occupation choice/opportunities (n=17) were highlighted. Reliance on others (n=16) also emerged. Additional to other categories was an overarching and universal distress arising from nystagmus affecting every aspect of everyday life.</p></sec><sec><st>Conclusion</st><p>Interviews revealed universally negative experiences of living with nystagmus that are previously unreported. Findings are similar to studies conducted for strabismus, in particular with respect to cosmetic impact. This study provides the content that is required to develop a nystagmus-specific quality of life tool.</p></sec>]]></description>
<dc:creator><![CDATA[McLean, R. J., Windridge, K. C., Gottlob, I.]]></dc:creator>
<dc:date>2012-04-19T02:01:43-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301183</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301183</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Muscles, Neurology]]></dc:subject>
<dc:title><![CDATA[Living with nystagmus: a qualitative study]]></dc:title>
<prism:publicationDate>2012-04-19</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300994v1?rss=1">
<title><![CDATA[Developmental macular disorders: phenotypes and underlying molecular genetic basis]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300994v1?rss=1</link>
<description><![CDATA[<p>The developmental macular disorders form part of a heterogeneous group of retinal conditions that are an important cause of visual impairment in children. The macular abnormality is present from birth and is usually non-progressive but visual loss may occur as a result of complications such as choroidal neovascularisation. To date, most of the causative genes have not been identified but with the advent of next generation sequencing, it is likely that the genetic basis of these disorders will soon be elucidated. Improved knowledge of the underlying molecular genetics and disease mechanisms will raise the possibility of future treatments for these disorders, for which there are no specific therapies available at the present time.</p>]]></description>
<dc:creator><![CDATA[Michaelides, M., Jeffery, G., Moore, A. T.]]></dc:creator>
<dc:date>2012-04-19T02:01:43-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300994</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300994</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Choroid]]></dc:subject>
<dc:title><![CDATA[Developmental macular disorders: phenotypes and underlying molecular genetic basis]]></dc:title>
<prism:publicationDate>2012-04-19</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301823v1?rss=1">
<title><![CDATA[Resistance, not tachyphylaxis or tolerance]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301823v1?rss=1</link>
<description><![CDATA[<p>We read with great interest the editorial &lsquo;Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?&rsquo; published recently in the <I>British Journal of Ophthalmology</I>.<cross-ref type="bib" refid="b1">1</cross-ref> The editorial discussed possible mechanisms behind decreased anti-vascular endothelial growth factor (anti-VEGF) response to neovascular age-related macular degeneration (AMD). Two articles were published in the same issue in which tachyphylaxis was suggested to occur during anti-VEGF treatment of wet AMD.<cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b3">3</cross-ref> The editorial and these papers stimulated us to comment on the discussion.</p><p>Tachyphylaxis is a phenomenon describing an acute and sudden decrease in drug response, which depends on the rate at which the stimulus is administered. Tachyphylaxis can be overcome by increasing the interval between doses. Typically, tachyphylaxis occurs in the central nervous system when stores of either neurotransmitters or receptors available for a drug are depleted or occupied, respectively, after a high-intensity prolonged stimulus (desensitisation).</p><p>In tolerance, the responsiveness...]]></description>
<dc:creator><![CDATA[Arjamaa, O., Minn, H.]]></dc:creator>
<dc:date>2012-04-17T02:01:28-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301823</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301823</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Resistance, not tachyphylaxis or tolerance]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301266v1?rss=1">
<title><![CDATA[Day-to-day variability in intraocular pressure in glaucoma and ocular hypertension]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301266v1?rss=1</link>
<description><![CDATA[<sec><st>Aims</st><p>To investigate the day-to-day repeatability of intraocular pressure (IOP) measurements.</p></sec><sec><st>Methods</st><p>A prospective cohort study of untreated patients presenting with primary open-angle glaucoma or ocular hypertension presenting with IOP&gt;21&nbsp;mm&nbsp;Hg. IOP was measured by masked Goldmann tonometry at 08:00, 11:00 and 16:00 at each of the three weekly visits. After starting travaprost (0.004%) to both eyes, the measurements were repeated for a further three weekly visits. Day-to-day repeatability was estimated before and after commencing medication and reported as the coefficient of repeatability and coefficient of variability.</p></sec><sec><st>Results</st><p>At the 8:00 time point, mean IOPs were 26.1 and 17.9&nbsp;mm&nbsp;Hg in the eye with higher pressure before and after starting treatment, respectively. Coefficient of repeatability and coefficient of variability were 6.8&nbsp;mm&nbsp;Hg and 10.0%, respectively, before treatment, and 4.6&nbsp;mm&nbsp;Hg and 10.5% on treatment. Therefore, before treatment and after starting medication the IOP lay within a range of &plusmn;20% of the mean IOP with 95% confidence.</p></sec><sec><st>Conclusions</st><p>The non-therapeutic variability from day to day significantly undermines the precision of IOP estimation and of the estimation of medication effectiveness even when the time of day is standardised in patients with primary open-angle glaucoma/ocular hypertension.</p></sec>]]></description>
<dc:creator><![CDATA[Rotchford, A. P., Uppal, S., Lakshmanan, A., King, A. J.]]></dc:creator>
<dc:date>2012-04-17T02:01:03-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301266</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301266</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Intraocular pressure, Glaucoma, Epidemiology]]></dc:subject>
<dc:title><![CDATA[Day-to-day variability in intraocular pressure in glaucoma and ocular hypertension]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300771v1?rss=1">
<title><![CDATA[Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300771v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>The syndrome of childhood blepharokeratoconjunctivitis (BKC) is frequently underestimated. While prevalent and aggressive among Indo-Pakistani/Middle-Eastern populations, we observe a recalcitrant destructive phenotype in white children/adolescents that persists into early adulthood and may require systemic immunosuppression.</p></sec><sec><st>Methods</st><p>A cohort of 10 white patients (20 eyes), median age 15.2 (range 6&ndash;27)&nbsp;years were identified among 62 patients with BKC attending a tertiary referral centre. Clinical features were graded and lid/conjunctiva swabs were performed, before instituting a hierarchical therapeutic protocol comprising lid hygiene, topical/systemic antibiotics, intensive topical glucocorticoids and systemic immunosuppression.</p></sec><sec><st>Results</st><p>The median duration of symptoms prior to presentation was 4.3 (range 1.2&ndash;16.3)&nbsp;years, with 14 eyes (nine patients) demonstrating 360&deg; peripheral corneal vascularisation associated with encroachment/involvement of the visual axis in 10 eyes (six patients). Corneal perforation(s) occurred in three eyes (two patients). Intensive topical glucocorticoids enabled disease control in 10 eyes (seven patients). In six eyes (three patients), persistent active disease necessitated systemic immunosuppression (azathioprine (2), mycophenolate mofetil (1), prednisolone (1)) achieving disease remission within three months with no adverse events reported.</p></sec><sec><st>Conclusions</st><p>Suboptimal treatment of BKC in white children may permit a progressively destructive sight-threatening phenotype, which may last into adulthood and require immunosuppression. Appropriate aggressive steroid-based and steroid-sparing strategies are vital for disease remission.</p></sec>]]></description>
<dc:creator><![CDATA[Hamada, S., Khan, I., Denniston, A. K., Rauz, S.]]></dc:creator>
<dc:date>2012-04-13T02:01:52-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300771</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300771</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents]]></dc:title>
<prism:publicationDate>2012-04-13</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300864v1?rss=1">
<title><![CDATA[Immediate removal of posteriorly dislocated lens fragments through sclerocorneal incision during cataract surgery]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300864v1?rss=1</link>
<description><![CDATA[<sec><st>Aim</st><p>To describe a new method of removing dislocated nuclear fragments smaller than one-fourth the size of the lens nucleus through the sclerocorneal incision made for cataract surgery.</p></sec><sec><st>Methods</st><p>Dislocated lens nuclear fragments on the surface of the retina were removed from six eyes of six consecutive patients. An anterior vitreous cutter with a 27-gauge chandelier endoilluminator (Twinlight illumination) tied to its sleeve was inserted into the eye through the incision made for cataract surgery and used for core vitrectomy. A fragmatome with another 27-gauge chandelier endoilluminator (Twinlight illumination) fibre was used to grasp and move the larger dislocated nuclear fragments into the anterior chamber where they were divided and removed.</p></sec><sec><st>Results</st><p>All dislocated nuclear fragments were removed through the incision for cataract surgery, and a posterior chamber lens was implanted in each patient without major complications.</p></sec><sec><st>Conclusions</st><p>The procedure can be used to remove dislocated lens nuclear fragments from the surface of the retina through the incision for cataract surgery. Neither a second surgery, which would require three ports, nor the body of instruments for vitreal surgery are needed with this procedure.</p></sec>]]></description>
<dc:creator><![CDATA[Nakasato, H., Uemoto, R., Kawagoe, T., Okada, E., Mizuki, N.]]></dc:creator>
<dc:date>2012-04-13T02:01:52-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300864</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300864</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Ophthalmologic surgical procedures, Lens and zonules]]></dc:subject>
<dc:title><![CDATA[Immediate removal of posteriorly dislocated lens fragments through sclerocorneal incision during cataract surgery]]></dc:title>
<prism:publicationDate>2012-04-13</prism:publicationDate>
<prism:section>Innovations</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301795v1?rss=1">
<title><![CDATA[Keratopigmentation: techniques and results]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301795v1?rss=1</link>
<description><![CDATA[<p>We read with great interest the article on keratopigmentation by Alio <I>et al</I>, and the letter on the subject by Segal <I>et al.</I><cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> Corneal tattooing under a lamellar pocket was described more than 25&nbsp;years ago, but the manual technique described by Alio <I>et al</I> seems to be easier, and when using a femtosecond laser, it is even more surgeon-friendly.<cross-ref type="bib" refid="b3">3</cross-ref> They published very good results that are undoubtedly related to their adequate technique, but also may be related to the nature of the dye (mineral micronised pigments). They had previously reported that, experimentally, this kind of dye showed no signs of pigment diffusion and practically no signs of inflammation.<cross-ref type="bib" refid="b4">4</cross-ref> They also reported good results in 40 patients in whom keratopigmentation was performed with cosmetic purposes.<cross-ref type="bib" refid="b5">5</cross-ref> We have some comments about their recent publication<cross-ref type="bib" refid="b1">1</cross-ref>: in table 1 it is...]]></description>
<dc:creator><![CDATA[Galvis, V., Tello, A.]]></dc:creator>
<dc:date>2012-04-04T02:01:28-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301795</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301795</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Keratopigmentation: techniques and results]]></dc:title>
<prism:publicationDate>2012-04-04</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301135v1?rss=1">
<title><![CDATA[Epithelial ingrowth cells after LASIK/ALTK (automated lamellar therapeutic keratoplasty): are they corneal epithelial stem cells?]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301135v1?rss=1</link>
<description><![CDATA[<p>Epithelial ingrowth (EI) is a severe and incompletely understood complication after laser-assisted in situ keratomileusis (LASIK). Its incidence is variable and cases requiring surgical removal occur with a frequency of 0.92%&ndash;2.2%.<cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> Here, we report the clinical, morphological and immunohistological features of EI cells of four patients, two LASIKs, one FemtoLASIK and one ALTK, with EI that needed surgical removal (<cross-ref type="fig" refid="fig1">figure 1A</cross-ref>). Immunohistochemistry was performed using antibodies against CK3, Muc5AC, CK15 and CK19 (differentiation markers) and against p63, BMI1, C/EBP  and BCRP/ABCG2 (stem cell markers) and Ki67 (proliferation marker).<cross-ref type="bib" refid="b3">3</cross-ref></p><p>Cytoplasm of superficial squamous cells strongly expressed CK3 with no expression of Muc5AC, CK19 or CK15. Nuclear expression of BMI1, p63 &alpha; and  and C/EBP  was seen in a majority of cells on EI specimens tested. BCRP/ABCG2 was expressed on the cell membrane and in the cytoplasm and in the nucleus...]]></description>
<dc:creator><![CDATA[Nicolas, M., Abouzeid, H., Deprez, M., Hafezi, F., Munier, F. L., Varga, Z., Majo, F.]]></dc:creator>
<dc:date>2012-04-04T02:01:28-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301135</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301135</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Epithelial ingrowth cells after LASIK/ALTK (automated lamellar therapeutic keratoplasty): are they corneal epithelial stem cells?]]></dc:title>
<prism:publicationDate>2012-04-04</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301719v1?rss=1">
<title><![CDATA[Comment on: 'Plasma, aqueous and vitreous homocysteine levels in proliferative diabetic retinopathy']]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301719v1?rss=1</link>
<description><![CDATA[<p>We read with great interest the paper by <I>Lim et al</I><cross-ref type="bib" refid="b1">1</cross-ref> entitled &lsquo;Plasma, aqueous and vitreous homocysteine levels in proliferative diabetic retinopathy&rsquo;. We want to add a short notation to help the readers interpret the results of the study objectively. We do congratulate the authors for their valuable article. It is not so easy to collect simultaneously three different samples and make these assessments precisely. However, some highlighted issues should also be discussed:<l type="tab"><li><p>First, when selecting the patient and control groups, measuring blood levels of vitamin B<SUB>12</SUB> and folate might be beneficial and very important to eliminate the deficiency of these vitamins, which may increase the levels of blood homocysteine. Although the main aim of the study is to measure homocysteine levels, there was no vitamin B<SUB>12</SUB> or folate measurement. The individuals having low vitamin B<SUB>12</SUB> and folate levels could be excluded from the study. Thus, the authors...]]></description>
<dc:creator><![CDATA[Ayata, A., Yildirim, Y., Ozcan, O.]]></dc:creator>
<dc:date>2012-04-01T02:02:06-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301719</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301719</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Comment on: 'Plasma, aqueous and vitreous homocysteine levels in proliferative diabetic retinopathy']]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301766v1?rss=1">
<title><![CDATA[Phenotypic plasticity of human umbilical vein endothelial cells]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301766v1?rss=1</link>
<description><![CDATA[<p>We read the article of Browning <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> about comparative gene expression profiling of human umbilical vein endothelial cells (HUVEC) and ocular vascular endothelial cells with interest. The authors report that primary HUVEC (commercially bought, unpassaged) show enrichment for probe sets involved in embryological development while ocular microvascular endothelial cells (choroidal and retinal) isolated from postmortem human globes 49&ndash;52&nbsp;h after death demonstrated enrichment for probe sets for MHC classes I and II, immune responses and cell signal transduction. Postmortem artefact, including cessation of circulation, needs to be excluded as a possible cause of inflammatory gene expression, which we accept is non-trivial to perform but is important as death is recognised as pro-inflammatory. Following gene profiling of the three cell monocultures, the authors go on to compare proliferation responses and insulin-like growth factor signalling in retinal and choroidal endothelial cells only. The authors suggest that the differences between the...]]></description>
<dc:creator><![CDATA[Leach, L., Hamilton, R. D., Foss, A. J. E.]]></dc:creator>
<dc:date>2012-04-01T02:02:06-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301766</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301766</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Phenotypic plasticity of human umbilical vein endothelial cells]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301352v1?rss=1">
<title><![CDATA[The effect of riboflavin-ultraviolet A-induced collagen cross-linking on intraocular pressure measurement: an experimental study]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301352v1?rss=1</link>
<description><![CDATA[<sec><st>Purpose</st><p>To investigate the effect of corneal collagen cross-linking (CCL) on tonopen measurements of intraocular pressure (IOP).</p></sec><sec><st>Methods</st><p>CCL with 0.1% riboflavin solution and 30&nbsp;min of ultraviolet A radiation was performed on the right eye of 15 New Zealand albino adult rabbits (1.8&ndash;2.4&nbsp;kg) (15 eyes). The left eye served as control. IOP was measured by a pressure transducer system (true IOP) and by the tonopen hand-held device (corneal applanation tonometer) before treatment, at 1&nbsp;week, 1&nbsp;month and 3&nbsp;months following CCL. Reference pressure in the globe was increased by increments of 10&nbsp;mm&nbsp;Hg from 10 to 40&nbsp;mm&nbsp;Hg, using an anterior chamber infusion on a stand with variable height, and tonopen IOP measurements were recorded for each reference pressure in both eyes.</p></sec><sec><st>Results</st><p>Before CCL, tonopen readings were similar between the two eyes (p&gt;0.05). Tonopen underestimated the true IOP in all cases. Following CCL treatment, IOP measurements were significantly higher in the treated eye, at all time intervals (0.005&lt;p&lt;0.03). The most significant difference between true and measured IOP was noted at a reference pressure of 20&nbsp;mm&nbsp;Hg.</p></sec><sec><st>Conclusions</st><p>IOP measurements following CCL are overestimated by the tonopen, probably due to increased stiffness of the treated cornea.</p></sec>]]></description>
<dc:creator><![CDATA[Livny, E., Kaiserman, I., Hammel, N., Livnat, T., Zadok, D., Israel, K., Bahar, I.]]></dc:creator>
<dc:date>2012-03-30T02:01:24-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301352</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301352</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[The effect of riboflavin-ultraviolet A-induced collagen cross-linking on intraocular pressure measurement: an experimental study]]></dc:title>
<prism:publicationDate>2012-03-30</prism:publicationDate>
<prism:section>Original articles - Laboratory science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301602v1?rss=1">
<title><![CDATA[Author's response]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301602v1?rss=1</link>
<description><![CDATA[<p>I would like to thank Khalifa <I>et al</I>. We too believe that simulation technology is here to stay and that it can only improve with its further development and more research in software validation, highlighting its strengths and weaknesses. To this aim, our group has completed one such validation trial which we hope to share with the published community shortly.</p><p>Regarding the cost of these systems, we agree that these are currently restrictive (although we have already witnessed a substantial drop in price). We think that, for this reason, simulation based training works better on a regional training basis rather than individual hospitals investing heavily for a limited number of trainees. However, the increased demand caused by higher trainee to machine ratios will raise issues regarding how much minimum training will be required and for how long. Studies plotting learning curves required to reach standards set by validation trials are thus...]]></description>
<dc:creator><![CDATA[Spiteri, A.]]></dc:creator>
<dc:date>2012-03-28T02:02:40-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301602</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301602</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked]]></dc:subject>
<dc:title><![CDATA[Author's response]]></dc:title>
<prism:publicationDate>2012-03-28</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300654v1?rss=1">
<title><![CDATA[Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300654v1?rss=1</link>
<description><![CDATA[<p>The introduction of anti-vascular endothelial growth factor (anti-VEGF) drugs to ophthalmology over the past 7&nbsp;years has revolutionised the treatment of exudative age-related macular degeneration (AMD) and holds great promise for diabetic macular oedema, branch and central retinal vein occlusions, and retinopathy of prematurity. Each of the three available drugs (pegaptanib, bevacizumab and ranibizumab) was eagerly embraced by surgeons, but the subsequent clinical results have been mixed, and the regulatory hurdles, particularly those regarding off-label use of bevacizumab, have been challenging.</p><p>Into this mix enters aflibercept (VEGF Trap-eye (VTE); Eylea, Regeneron, Tarrytown, New York, USA), for which the US Food and Drug Administration granted approval for the treatment of subfoveal choroidal neovascularisation due to AMD on 18 November 2011. In contrast to the antibody-based VEGF binding strategy used by ranibizumab and bevacizumab, the VTE incorporates the second binding domain of the VEGFR-1 receptor and the third domain of the VEGFR-2 receptor.<cross-ref type="bib"...]]></description>
<dc:creator><![CDATA[Stewart, M. W.]]></dc:creator>
<dc:date>2012-03-23T02:01:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300654</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300654</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Retina, Unlocked, Epidemiology]]></dc:subject>
<dc:title><![CDATA[Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug]]></dc:title>
<prism:publicationDate>2012-03-23</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301168v1?rss=1">
<title><![CDATA[Deep anterior lamellar keratoplasty using an original manual technique]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301168v1?rss=1</link>
<description><![CDATA[<sec><st>Aims</st><p>To evaluate the clinical findings and visual outcomes of deep anterior lamellar keratoplasty (DALK) using an original manual dissection technique.</p></sec><sec><st>Methods</st><p>288 eyes (268 patients) with corneal pathologies without endothelial involvement were treated by DALK using an original manual dissection technique guided by a calibrated knife incision based on ultrasonic pachimetry values. Clinical records were examined retrospectively at 2&nbsp;months, 6&nbsp;months, 1&nbsp;year and 2&nbsp;years. The following outcomes were measured: visual acuity, topographic parameters, endothelial cell density and recipient stromal residue thickness.</p></sec><sec><st>Results</st><p>At the 2-year postoperative follow-up, the mean logarithm of the minimum angle of resolution best spectacle corrected visual acuity (BSCVA) was 0.131&plusmn;0.087 and topographic astigmatism was 2.87&plusmn;1.57 diopters. In 12 cases (4.2%) a perforation of Descemet's membrane required conversion of the procedure to penetrating keratoplasty. Mean optical coherence tomography (OCT) residue thickness (measured in 82 eyes with OCT Visante) was 31.63&plusmn;24.57&nbsp;&mu;m; lower values of recipient residue thickness were significantly associated with higher BSCVA (Spearman coefficient 0.635, p&lt; 0.001).</p></sec><sec><st>Conclusion</st><p>DALK using a dry manual dissection technique provides visual, refractive and clinical results comparable to other deep lamellar techniques. Eyes with lower values of recipient residue thickness are associated with better visual acuity.</p></sec>]]></description>
<dc:creator><![CDATA[Rama, P., Knutsson, K. A., Razzoli, G., Matuska, S., Vigano, M., Paganoni, G.]]></dc:creator>
<dc:date>2012-03-18T02:01:45-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301168</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301168</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Ophthalmologic surgical procedures, Optic nerve, Optics and refraction]]></dc:subject>
<dc:title><![CDATA[Deep anterior lamellar keratoplasty using an original manual technique]]></dc:title>
<prism:publicationDate>2012-03-18</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301658v1?rss=1">
<title><![CDATA[Normative optical coherence tomography measurements in children]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301658v1?rss=1</link>
<description><![CDATA[<p>Optical coherence tomography (OCT) has gained popularity in clinical ophthalmic management by providing detailed visualisation and quantification of ocular structures. The most common clinical use of this technology is in glaucoma, retina diseases, neuro-ophthalmology and anterior segment applications. Recent technological improvement leads to the introduction of spectral-domain OCT (SD-OCT) that offers higher scanning speeds, higher scan densities and better resolution than earlier generations of this technology. The ability to visualise areas of interest with a high acquisition rate SD-OCT imager along with the ability to quantify structures expands the utility of OCT to new clinical territories, such as children and other poorly compliant populations. In order to make full use of the OCT information, a comparison with population-derived normative data is needed to identify deviations from the normal range. Unfortunately, only limited information is available for persons &lt;18&nbsp;years of age for any of the commercially available OCTs.</p><p>Several studies have demonstrated...]]></description>
<dc:creator><![CDATA[Wollstein, G., Schuman, J. S.]]></dc:creator>
<dc:date>2012-03-17T02:01:02-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301658</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301658</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Public health, Angle, Intraocular pressure, Glaucoma]]></dc:subject>
<dc:title><![CDATA[Normative optical coherence tomography measurements in children]]></dc:title>
<prism:publicationDate>2012-03-17</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300983v1?rss=1">
<title><![CDATA[Clinical outcome of the artificial iris diaphragm in silicone oil surgery]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300983v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Some eyes require long-term silicone oil tamponade. Problems arise in aphakic eyes with iris defects or hypotony, because an inferior iridectomy can not prevent silicone oil from entering the anterior chamber causing keratopathy and glaucoma. The artificial iris diaphragm was developed to prevent these complications.</p></sec><sec><st>Methods</st><p>In this retrospective case series, 94 consecutive aphakic eyes of 94 patients received an artificial iris diaphragm and a silicone oil tamponade. All eyes had hypotony or iris defects. The primary outcome measure was the retention of silicone oil behind the iris diaphragm. Secondary outcome measures included visual acuity, intraocular pressure and surgical revisions.</p></sec><sec><st>Results</st><p>The mean follow-up time was 586&nbsp;days. No silicone oil in the anterior chamber at the last follow-up visit was found in 58 cases (61.7%). The Kaplan&ndash;Meier survival analysis returned a mean survival time for a functional diaphragm of 1227&nbsp;days. Keratopathy improved in 55.3% at least temporarily, and vision improved or remained stable in 38.2% until last follow-up. The diaphragm was more successful when the underlying disease was trauma or congenital malformation.</p></sec><sec><st>Conclusions</st><p>The artificial iris diaphragm often retained silicone oil from the anterior chamber in severely damaged eyes. It can be useful to prevent phthisis and preserve vision.</p></sec>]]></description>
<dc:creator><![CDATA[Hermann, M. M., Muether, P. S., Kuhn, L., Kirchhof, B., Fauser, S.]]></dc:creator>
<dc:date>2012-03-09T02:03:56-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300983</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300983</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Cornea, Intraocular pressure, Lens and zonules, Ocular surface, Glaucoma]]></dc:subject>
<dc:title><![CDATA[Clinical outcome of the artificial iris diaphragm in silicone oil surgery]]></dc:title>
<prism:publicationDate>2012-03-09</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300996v1?rss=1">
<title><![CDATA[Use of iris recognition camera technology for the quantification of corneal opacification in mucopolysaccharidoses]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300996v1?rss=1</link>
<description><![CDATA[<p>Mucopolysaccharidoses (MPS) can cause corneal opacification that is currently difficult to objectively quantify. With newer treatments for MPS comes an increased need for a more objective, valid and reliable index of disease severity for clinical and research use. Clinical evaluation by slit lamp is very subjective and techniques based on colour photography are difficult to standardise. In this article the authors present evidence for the utility of dedicated image analysis algorithms applied to images obtained by a highly sophisticated iris recognition camera that is small, manoeuvrable and adapted to achieve rapid, reliable and standardised objective imaging in a wide variety of patients while minimising artefactual interference in image quality.</p>]]></description>
<dc:creator><![CDATA[Aslam, T. M., Shakir, S., Wong, J., Au, L., Ashworth, J.]]></dc:creator>
<dc:date>2012-03-06T02:01:40-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300996</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300996</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Use of iris recognition camera technology for the quantification of corneal opacification in mucopolysaccharidoses]]></dc:title>
<prism:publicationDate>2012-03-06</prism:publicationDate>
<prism:section>Innovations</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301531v1?rss=1">
<title><![CDATA[Self-enucleation: forget Freud and Oedipus, it's all about untreated psychosis]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301531v1?rss=1</link>
<description><![CDATA[<p>Self-enucleation is a rare but serious ophthalmological and psychiatric emergency. It has traditionally been considered to be the result of psycho-sexual conflicts, including those arising from Freud's Oedipal complex and Christian religious teaching. However, an analysis of published case reports suggests that self-enucleation is a result of psychotic illnesses such as schizophrenia. Early treatment with antipsychotic medication in the case of unilateral or threatened self-enucleation might prevent some cases of blindness.</p>]]></description>
<dc:creator><![CDATA[Large, M. M., Nielssen, O. B.]]></dc:creator>
<dc:date>2012-02-28T05:45:57-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301531</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301531</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Vision, Press releases, Neurology]]></dc:subject>
<dc:title><![CDATA[Self-enucleation: forget Freud and Oedipus, it's all about untreated psychosis]]></dc:title>
<prism:publicationDate>2012-02-28</prism:publicationDate>
<prism:section>Innovations</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301016v1?rss=1">
<title><![CDATA[Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301016v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>The preservation of globe integrity has always been a major concern during the treatment of retinoblastoma for fear of extraocular or metastatic spread. Intravitreal chemotherapy has been attempted as a desperate salvage therapy only for eyes with refractory retinoblastoma. Published data on the safety and efficacy of this route are, however, limited.</p></sec><sec><st>Methods</st><p>A modified technique of intravitreal injection in eyes with retinoblastoma is described. All children with retinoblastoma who received one or more intravitreal injections using this technique were retrospectively reviewed concerning ocular complications of the injection procedure as well as clinical or histopathological evidence of tumour spread.</p></sec><sec><st>Results</st><p>30 eyes of 30 children with retinoblastoma received a total of 135 intravitreal injections, with a median follw-up duration of 13.5&nbsp;months. No extraocular spread was seen on clinical follow-up in any patients and there was no tumour contamination of the retrieved entry sites histopathologically analysed among the five enucleated eyes. No significant ocular side effects were observed except transient localised vitreous haemorrhage (3/135).</p></sec><sec><st>Conclusion</st><p>This technique is potentially safe and effective at a low cost and may play a promising role, especially in the treatment of recurrent and/or resistant vitreous disease in retinoblastoma, as an alternative to enucleation and/or external beam radiotherapy. However, this treatment should not replace the primary standard of care of retinoblastoma and should not be considered in group E eyes. Its application should be approved by an ophthalmological-oncological team and it should be performed by an experienced eye surgeon in a tertiary referral centre after careful selection of a tumour-free injection site.</p></sec>]]></description>
<dc:creator><![CDATA[Munier, F. L., Soliman, S., Moulin, A. P., Gaillard, M.-C., Balmer, A., Beck-Popovic, M.]]></dc:creator>
<dc:date>2012-02-24T02:02:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301016</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301016</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Vitreous]]></dc:subject>
<dc:title><![CDATA[Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track]]></dc:title>
<prism:publicationDate>2012-02-24</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300829v1?rss=1">
<title><![CDATA[Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300829v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>To describe the technique of intravitreal chemotherapy preceded by subconjunctival chemotherapy for the treatment of vitreous seeds in advanced stage retinoblastoma.</p></sec><sec><st>Methods</st><p>This non-comparative interventional case series retrospectively reviewed the medical records and postenucleation histopathological findings of two patients who presented within weeks of each other with bilateral retinoblastoma, Reese&ndash;Ellsworth (R-E) stage Vb in the worse eye. Both patients had failed systemic chemotherapy prior to receiving a single treatment of 0.5&nbsp;ml (5&nbsp;mg per 0.5&nbsp;ml) of subconjunctival carboplatin, through which 0.05&nbsp;ml (3&nbsp;mcg per 0.05&nbsp;ml) of carboplatin was injected into the vitreous (Case 2 received 0.1&nbsp;ml of intravitreal carboplatin). The subconjunctival chemotherapy was given to reduce the risk of orbital tumour seeding following intravitreal injection. Following enucleation, ocular toxicity and the presence or absence of viable tumour cells at the intravitreal injection site were recorded.</p></sec><sec><st>Results</st><p>Histopathological examination did not reveal patency of the pars plana intravitreal penetration site in either case at 6&nbsp;weeks post-treatment nor was malignant seeding detected in the area of injection. Examination of the two enucleated eyes did not demonstrate structural toxicity to the cornea, anterior segment, iris or retina. Additionally, both cases were followed for over 37&nbsp;months post-treatment, without the occurrence of orbital malignancy.</p></sec><sec><st>Conclusions</st><p>Injecting a bleb of subconjunctival chemotherapy prior to intravitreal drug delivery appeared to mitigate the risk of orbital tumour seeding in two patients with advanced stage retinoblastoma. Incorporating this technique may allow further investigation of intravitreal chemotherapy for the treatment of vitreous seeds in retinoblastoma.</p></sec>]]></description>
<dc:creator><![CDATA[Smith, S. J., Pulido, J. S., Salomao, D. R., Smith, B. D., Mohney, B.]]></dc:creator>
<dc:date>2012-02-24T02:02:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300829</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300829</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds]]></dc:title>
<prism:publicationDate>2012-02-24</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301562v1?rss=1">
<title><![CDATA[L-PGD synthase: does its concentration in the optic nerve subarachnoid space correlate to the structural damage of the nerve in papilloedema or glaucoma?]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301562v1?rss=1</link>
<description><![CDATA[<p>Professor Hanspeter Esriel Killer <I>et al</I>, in a series of excellent original articles on cerebrospinal fluid (CSF) dynamics in the subarachnoid spaces (SAS) of the optic nerve, holds the view that CSF is compartmentalised within the trabecular SAS of the optic nerve causing stasis or reduced CSF flow.<cross-ref type="bib" refid="b1">1</cross-ref> As a result, the CSF composition is altered. Increased concentration of molecules such as Lipocalin-type prostaglandin D synthase (L-PGDS) supposedly causes toxic damage to the optic nerve. The ratio of concentration of L-PGDS in the subarachnoid spaces of the optic nerve to that of lumbar puncture (ON:LP) is high in all but five of the reported cases. Two eyes of idiopathic intracranial hypertension cases, a single eye of the control subject reported in <I>BJO</I><cross-ref type="bib" refid="b1">1</cross-ref> and two eyes with atypical normotensive glaucoma reported in 2007<cross-ref type="bib" refid="b2">2</cross-ref> show low values. Is this a significant finding? Does the ON:LP value...]]></description>
<dc:creator><![CDATA[Raja, S. A.]]></dc:creator>
<dc:date>2012-02-22T02:02:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301562</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301562</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[L-PGD synthase: does its concentration in the optic nerve subarachnoid space correlate to the structural damage of the nerve in papilloedema or glaucoma?]]></dc:title>
<prism:publicationDate>2012-02-22</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301588v1?rss=1">
<title><![CDATA[The future of surgical assessment]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301588v1?rss=1</link>
<description><![CDATA[<p>We took great interest in the review by Spiteri <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> regarding the teaching and assessment of cataract surgery skills. We have recently employed the Kitaro wet and dry lab system at the University of Rochester and have found the accuracy of the simulation to be excellent. We believe the fidelity of this system will fundamentally change the role of phacoemulsification training outside the operating theatre. The authors mention virtual reality systems as an alternative to human and animal wet lab models, but we have found the cost of these systems restrictive. The major advantages of the virtual reality system are its instantaneous feedback, its objectivity and its standardisation, but a minority of training programmes in the USA are able to afford the expense.</p><p>Regarding assessment of operative performance using video-based methods, we have found the major impediment is time. For an attending to review a single cataract surgery...]]></description>
<dc:creator><![CDATA[Khalifa, Y. M., Hines, M. A., Gearinger, M.]]></dc:creator>
<dc:date>2012-02-22T02:02:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301588</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301588</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[The future of surgical assessment]]></dc:title>
<prism:publicationDate>2012-02-22</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301099v1?rss=1">
<title><![CDATA[Temporal interactive response is resistant to cloudy ocular media in the slow double-stimulation multifocal electroretinogram]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301099v1?rss=1</link>
<description><![CDATA[<sec><st>Aim</st><p>To examine the influence of cloudy media on the slow double-stimulation multifocal electroretinogram (mfERG).</p></sec><sec><st>Methods</st><p>Slow double-stimulation mfERG responses were measured from 26 subjects with normal ocular health under normal and light scattering conditions (induced using acrylic sheets) (Experiment 1) and another nine cataract patients before and after cataract surgery (Experiment 2). The amplitudes and implicit times of the first (M<sup>1</sup>) and second (M<sup>2</sup>) stimulation were compared under normal and light scattering conditions in Experiment 1 and they were compared under precataract and postcataract surgery in Experiment 2.</p></sec><sec><st>Results</st><p>Compared with control conditions (normal and postcataract surgery), the M<sup>1</sup> amplitude in the central region was significantly reduced in light scattering conditions (acrylic sheets and precataract surgery); the M<sup>2</sup> amplitude and both M<sup>1</sup> and M<sup>2</sup> implicit times of all regions examined were moderately affected in precataract surgery. The M<sup>1</sup>:M<sup>2</sup> amplitude ratio and implicit time ratio were virtually unaffected in cloudy media for either central or mid-peripheral regions.</p></sec><sec><st>Conclusion</st><p>Cloudy media affects the mfERG amplitude and implicit time in the slow double-stimulation, but does not affect the response ratio (ie, M<sup>1</sup>:M<sup>2</sup> amplitude ratio and implicit time ratio) between the two stimulations. This suggests that the ratio analysis can be applied in patients with mild to moderately cloudy ocular media to evaluate the functional integrity of the retina.</p></sec>]]></description>
<dc:creator><![CDATA[Ho, W.-C., Chu, P. H. W., Ng, Y.-F., Tong, P. P. C., Woo, V. C. P., Chan, H. H. L.]]></dc:creator>
<dc:date>2012-02-16T02:02:10-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301099</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301099</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lens and zonules]]></dc:subject>
<dc:title><![CDATA[Temporal interactive response is resistant to cloudy ocular media in the slow double-stimulation multifocal electroretinogram]]></dc:title>
<prism:publicationDate>2012-02-16</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301558v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2012-301558v1?rss=1</link>
<description><![CDATA[<p>We thank Drs Nazari and Rao<cross-ref type="bib" refid="b1">1</cross-ref> for their interest in our study. The diagnosis of 'latent tuberculosis (TB)' in the context of patients with concurrent uveitis is controversial and a careful use of terminology is required in order not to mislead readers. In our study,<cross-ref type="bib" refid="b2">2</cross-ref> the patients had uveitis and a positive tuberculin skin test, with all other causes of uveitis having been excluded. In these patients, we cannot be certain that the ocular inflammation is secondary to active replication of mycobacterium within the eye as none of our patients underwent intraocular tissue sampling for TB culture or PCR for mycobacterial DNA. Thus, we are reluctant to use the term &lsquo;ocular tuberculosis&rsquo;, which we agree is a condition, which involves secondary reactivation of <I>Mycobacterium tuberculosis</I> within the eye, and mislead our readers. For similar reasons, Bansal <I>et al</I><cross-ref type="bib" refid="b3">3</cross-ref> used the phrase &lsquo;uveitis with latent...]]></description>
<dc:creator><![CDATA[Ang, M., Chee, S.-P.]]></dc:creator>
<dc:date>2012-02-14T02:02:33-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301558</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301558</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2012-02-14</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300926v1?rss=1">
<title><![CDATA[Changing trends in the incidence of bleb-related infection in trabeculectomy]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300926v1?rss=1</link>
<description><![CDATA[<sec><st>Aim</st><p>To investigate the incidence of late onset bleb-related infection (BRI) following Mitomycin C (MMC) augmented trabeculectomy procedures at a single institution.</p></sec><sec><st>Methods</st><p>This was a retrospective case series analysis of late onset BRI, defined as either blebitis or endophthalmitis occurring at least 1&nbsp;month following a glaucoma filtration procedure. Data collected from hospital charts included the position of the conjunctival flap base. Two cohorts were examined: the first a sample of 194 intraoperative MMC augmented trabeculectomies undertaken over a 4-year period from 1993 to 1997, and the second a sample of 764 MMC trabeculectomies performed in a 4-year period between the years 1999 and 2005.</p></sec><sec><st>Results</st><p>A total of 11 cases of BRI (cumulative incidence 5.7%) were identified in the cohort from 1993 to 1997. BRI cases had trabeculectomies performed with a limbus-based conjunctival flap and presented at a median IQR 14.8 (9.4&ndash;42.9) months after surgery. In the 1999&ndash;2005 cohort, nine cases of BRI were identified (cumulative incidence 1.2%). All these BRI cases had a fornix-based conjunctival flap and presented at a median IQR 19.2 (6.1&ndash;44.1) months after trabeculectomy surgery.</p></sec><sec><st>Conclusion</st><p>This study found that the incidence of BRI was higher in MMC augmented trabeculectomy shortly after the introduction of MMC, but subsequently reduced to a lower level. While many changes in surgical technique had occurred in the intervening period, the most significant change was from limbus-based to fornix-based conjunctival flap. However, the retrospective nature of the study prevents the authors from concluding that there is a causative relationship between changes in surgical technique and BRI.</p></sec>]]></description>
<dc:creator><![CDATA[Rai, P., Kotecha, A., Kaltsos, K., Ruddle, J. B., Murdoch, I. E., Bunce, C., Barton, K.]]></dc:creator>
<dc:date>2012-02-14T02:02:33-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300926</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300926</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Ophthalmologic surgical procedures, Angle, Choroid, Eye (globe), Intraocular pressure, Glaucoma]]></dc:subject>
<dc:title><![CDATA[Changing trends in the incidence of bleb-related infection in trabeculectomy]]></dc:title>
<prism:publicationDate>2012-02-14</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301164v1?rss=1">
<title><![CDATA[Simple limbal epithelial transplantation (SLET): a novel surgical technique for the treatment of unilateral limbal stem cell deficiency]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301164v1?rss=1</link>
<description><![CDATA[<p>This study describes a novel surgical technique of limbal transplantation, which combines the benefits of existing techniques while avoiding their difficulties. Six patients with unilateral and total limbal stem cell deficiency following ocular surface burns underwent a single-stage procedure. A 2<FONT FACE="arial,helvetica">x</FONT>2&nbsp;mm strip of donor limbal tissue was obtained from the healthy eye and divided into eight to ten small pieces. After surgical preparation of the recipient ocular surface, these tiny limbal transplants were distributed evenly over an amniotic membrane placed on the cornea. After surgery, a completely epithelialised, avascular and stable corneal surface was seen in all recipient eyes by 6 weeks, and this was maintained at a mean&plusmn;SD follow-up of 9.2&plusmn;1.9&nbsp;months. Visual acuity improved from worse than 20/200 in all recipient eyes before surgery to 20/60 or better in four (66.6%) eyes, while none of the donor eyes developed any complications. This technique requires less donor tissue than previously used for conventional autografting and does not need a specialist laboratory for cell expansion. Although long-term results are awaited, this simple limbal epithelial transplantation promises to be an easy and effective technique for treating unilateral limbal stem cell deficiency following ocular burns.</p>]]></description>
<dc:creator><![CDATA[Sangwan, V. S., Basu, S., MacNeil, S., Balasubramanian, D.]]></dc:creator>
<dc:date>2012-02-10T02:01:57-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301164</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301164</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Simple limbal epithelial transplantation (SLET): a novel surgical technique for the treatment of unilateral limbal stem cell deficiency]]></dc:title>
<prism:publicationDate>2012-02-10</prism:publicationDate>
<prism:section>Innovations</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300426v1?rss=1">
<title><![CDATA[Blindness and visual impairment due to uncorrected refractive error in sub-Saharan Africa: review of recent population-based studies]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300426v1?rss=1</link>
<description><![CDATA[<sec><st>Aim</st><p>The authors aimed to review published data on uncorrected refractive error (URE) as a cause of blindness and visual impairment in adults aged &ge;40&nbsp;years in sub-Saharan Africa (SSA).</p></sec><sec><st>Methods</st><p>Data were extracted from population-based prevalence surveys measuring presenting visual acuity (PVA). Results from 11 surveys performed in 10 countries in SSA, encompassing 39 458 people aged &ge;40&nbsp;years and older, are presented.</p></sec><sec><st>Results</st><p>The prevalence of blindness (PVA&lt;3/60 in better eye) ranged from 1.1% in an urban district of Cameroon to 7.9% in a rural district in Ethiopia. More than half of studies (6/11) reported no blindness due to URE. The proportion of moderate visual impairment (PVA &le;6/60 and &gt;6/18) due to URE ranged from 12.3% to 57.1%. Excluding two studies that included uncorrected aphakia as part of URE, the highest proportion of blindness and severe visual impairment due to uncorrected aphakia was found in Gambia (15.2%) and Nigeria (15.8%), respectively.</p></sec><sec><st>Conclusion</st><p>Although URE is a leading cause of visual impairment, it does not represent a major cause of blindness in SSA.</p></sec>]]></description>
<dc:creator><![CDATA[Sherwin, J. C., Lewallen, S., Courtright, P.]]></dc:creator>
<dc:date>2012-02-08T02:02:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300426</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300426</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lens and zonules, Optic nerve, Vision, Neurology, Optics and refraction, Epidemiology]]></dc:subject>
<dc:title><![CDATA[Blindness and visual impairment due to uncorrected refractive error in sub-Saharan Africa: review of recent population-based studies]]></dc:title>
<prism:publicationDate>2012-02-08</prism:publicationDate>
<prism:section>Global issues</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301134v1?rss=1">
<title><![CDATA[RP1 and retinitis pigmentosa: report of novel mutations and insight into mutational mechanism]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301134v1?rss=1</link>
<description><![CDATA[<sec><st>Background/aim</st><p>Retinitis pigmentosa (RP) is the commonest form of retinal dystrophy and is usually inherited as a monogenic trait but with remarkable genetic heterogeneity. RP1 is one of the earliest identified disease genes in RP with mutations in this gene known to act both recessively and dominantly although the mutational mechanism remains unclear. This study is part of our ongoing effort to characterise RP in Saudi Arabia at the molecular level.</p></sec><sec><st>Methods</st><p>Homozygosity mapping and candidate gene analysis.</p></sec><sec><st>Results</st><p>The authors have identified four novel mutations, all recessive, in a number of families with a typical RP phenotype.</p></sec><sec><st>Conclusion</st><p>The distribution of these novel and previously reported RP1 mutations makes it challenging to describe a unifying mutational mechanism for dominant versus recessive RP1-related RP.</p></sec>]]></description>
<dc:creator><![CDATA[Al-Rashed, M., Abu Safieh, L., Alkuraya, H., Aldahmesh, M. A., Alzahrani, J., Diya, M., Hashem, M., Hardcastle, A. J., Al-Hazzaa, S. A. F., Alkuraya, F. S.]]></dc:creator>
<dc:date>2012-02-08T02:02:11-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301134</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301134</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Eye (globe), Retina]]></dc:subject>
<dc:title><![CDATA[RP1 and retinitis pigmentosa: report of novel mutations and insight into mutational mechanism]]></dc:title>
<prism:publicationDate>2012-02-08</prism:publicationDate>
<prism:section>Original articles - Laboratory science</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301424v1?rss=1">
<title><![CDATA[Reporting outcomes of randomised controlled trials]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301424v1?rss=1</link>
<description><![CDATA[<p>I have concerns about the study on Candida fungal keratitis by Matsumoto <I>et al</I>.<cross-ref type="bib" refid="b1">1</cross-ref> Despite using the word &lsquo;randomised&rsquo; in the Methods section, the patients were not randomised at all but merely alternately allocated into each treatment arm. Randomisation implies that participants do not know what each patient will receive. The trial was started in 2001 with the first patient receiving fluconazole yet the text suggests that the second subject was only recruited in 2002 when micafungin became available. I do not see how you can start a study before both treatments are available. If one accepts that this was a trial then there are multiple additional issues that need to be addressed. The study began in 2001 around the same time that the Consort statement was published.<cross-ref type="bib" refid="b2">2&ndash;4</cross-ref><cross-ref type="bib" refid="b3"></cross-ref><cross-ref type="bib" refid="b4"></cross-ref> Did the authors register the trial at a trial registry? The paper does not...]]></description>
<dc:creator><![CDATA[Wilkins, M. R.]]></dc:creator>
<dc:date>2012-01-23T23:38:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301424</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301424</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Reporting outcomes of randomised controlled trials]]></dc:title>
<prism:publicationDate>2012-01-23</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301351v1?rss=1">
<title><![CDATA[Authors' response: Eyelid avulsion repair with bi-canalicular silicone stenting without medial canthal tendon reconstruction]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301351v1?rss=1</link>
<description><![CDATA[<p>In their article &lsquo;Eyelid avulsion repair with bi-canalicular silicone stenting without medial canthal tendon reconstruction&rsquo;,<cross-ref type="bib" refid="b1">1</cross-ref> Naing Tint and associates highlighted the successful restoration of the normal anatomy of the medial canthal tendon with bi-canalicular stenting alone. The authors stressed that a prerequisite for the successful use of Crawford stents for anatomical realignment is keeping the tube under sufficient tension to restore and maintain the normal position of the posterior limb of the medial canthal tendon.</p><p>We propose that pigtail probing would better serve this purpose than standard bi-canalicular stenting because the Crawford stent is tied to itself and the knot is left loose inside the nasal cavity. The tension that is achieved at the conclusion of surgery may not be sustained.</p><p>In case of pigtail probing, the required tension can be easily titrated by judiciously shortening the length of the silicone tube used until the desired anatomical result is reached...]]></description>
<dc:creator><![CDATA[Tawfik, H. A., Elsamkary, M.]]></dc:creator>
<dc:date>2012-01-23T23:38:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301351</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301351</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response: Eyelid avulsion repair with bi-canalicular silicone stenting without medial canthal tendon reconstruction]]></dc:title>
<prism:publicationDate>2012-01-23</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301245v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301245v1?rss=1</link>
<description><![CDATA[<p>We were surprised and disappointed that the editors did not follow the established practice of inviting a reply to the letter by Landers <I>et al</I> when it was submitted in June and then published in November.<cross-ref type="bib" refid="b1">1</cross-ref> Nevertheless, a response is in order.</p><p>We were interested to learn more about the good work Landers <I>et al</I> are doing.<cross-ref type="bib" refid="b2">2</cross-ref> It is important to differentiate between the retrospective analysis of clinical cases, even in outreach clinics and population-based samples.</p><p>They seem to have overlooked the work of Robin and others who have shown that when combined with a simple history and the measurement of visual acuity, frequency doubling technology threshold testing has a sensitivity of 89.5% and a specificity of 98.6% for the detection of glaucoma in population-based testing.<cross-ref type="bib" refid="b3">3</cross-ref> <cross-ref type="bib" refid="b4">4</cross-ref></p><p>The classification of glaucoma purely on disc cup proportion is useful, but simplistic. It depends heavily on disc...]]></description>
<dc:creator><![CDATA[Taylor, H. R., Keeffe, J. E.]]></dc:creator>
<dc:date>2011-12-16T07:38:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301245</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301245</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2011-12-16</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301241v1?rss=1">
<title><![CDATA[5.7 Times more expensive than liquid gold]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301241v1?rss=1</link>
<description><![CDATA[<p>We read the October issue of the <I>British Journal of Ophthalmology</I> and in particular the safety review of bevacizumab (Avastin) versus ranibizumab (Lucentis) by Schmucker <I>et al</I> with great interest.<cross-ref type="bib" refid="b1">1</cross-ref> NICE approved the use of Lucentis for the treatment of macular degeneration in February 2007. We are therefore surprised that 5&nbsp;years on debate regarding the use of Avastin versus Lucentis continues.</p><p>We thought your readership may be interested in the following graph:<f><inline-fig><link locator="bjophthalmol-2011-301241inf1"></inline-fig></f></p><p>The above graph represents the price in British pounds by volume. Lucentis is available in 0.2&nbsp;ml phials, although the treatment dose is only 0.05&nbsp;ml (0.05&nbsp;mg). Some of the liquid is lost in transfer between containers, and it is standard practice to discard the remainder between patients. According to the figures quoted in the <I>British Medical Journal</I>,<cross-ref type="bib" refid="b2">2</cross-ref> one treatment dose of Lucentis (&pound;740) is 8.7 times the price of treatment with Avastin (&pound;85). Price comparison was...]]></description>
<dc:creator><![CDATA[Bowler, G. S., Fayers, T., Gouws, P.]]></dc:creator>
<dc:date>2011-11-28T20:03:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301241</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301241</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[5.7 Times more expensive than liquid gold]]></dc:title>
<prism:publicationDate>2011-11-28</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301104v1?rss=1">
<title><![CDATA[A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-301104v1?rss=1</link>
<description><![CDATA[<p>We read the article entitled &lsquo;A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis&rsquo; by Wilkins and colleagues<cross-ref type="bib" refid="b1">1</cross-ref> with great interest. Although viral conjunctivitis is typically a self-limiting disease that resolves in 2&nbsp;weeks, we agree that an agent that reduces clinical symptoms and minimises shedding of infectious virus would be desirable given the morbidity and potential economic impact associated with an outbreak of viral conjunctivitis.<cross-ref type="bib" refid="b2">2</cross-ref> We have the following observations regarding the methodology and interpretation of the results.</p><p>Eighty-eight out of 111 randomised patients returned for review, that is, 23 patients dropped out. The authors should consider performing intention-to-treat analysis. The authors did not analyse those who did not return for follow-up. Those who dropped out might have done so due to discomfort after using dexamethasone and might have gone elsewhere for other treatment.</p><p>Topical steroids may have the potential side effect of promoting viral replication...]]></description>
<dc:creator><![CDATA[Wong, A. C.-m., Mak, S. T.]]></dc:creator>
<dc:date>2011-11-03T08:36:53-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301104</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301104</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis]]></dc:title>
<prism:publicationDate>2011-11-03</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300476v1?rss=1">
<title><![CDATA[Is high-resolution spectral domain optical coherence tomography reliable in nystagmus?]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300476v1?rss=1</link>
<description><![CDATA[<p>Recently, there has been an increased number of studies investigating retinal morphology in infantile nystagmus.<cross-ref type="bib" refid="b1">1&ndash;4</cross-ref><cross-ref type="bib" refid="b2"></cross-ref><cross-ref type="bib" refid="b3"></cross-ref><cross-ref type="bib" refid="b4"></cross-ref> Optical coherence tomography (OCT) studies in achromatopsia have shown progressive retinal changes.<cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b4">4</cross-ref> Most OCT software limits segmentation to the retinal nerve fibre layer and overall retinal thickness (RT). However, we have shown that outer nuclear layer (ONL), outer segment (OS) and foveal depth (FD) are important measurements in infantile nystagmus.<cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b5">5</cross-ref> Intraretinal thicknesses (FD, ONL, inner segment (IS) and OS) can be derived using reflectivity-based segmentation using ImageJ<cross-ref type="bib" refid="b1">1</cross-ref> (<cross-ref type="fig" refid="fig1">figure 1</cross-ref>). External limiting membrane (ELM) and inner&ndash;outer segment junction (IS/OS) reflectivity changes have been reported in blue cone monochromatism and achromatopsia. However, it is unclear whether nystagmus allows reproducible OCT measurements of thickness and reflectivity.</p><p>We used SOCT Copernicus HR to obtain three-dimensional...]]></description>
<dc:creator><![CDATA[Thomas, M. G., Kumar, A., Thompson, J. R., Proudlock, F. A., Straatman, K., Gottlob, I.]]></dc:creator>
<dc:date>2011-09-27T15:16:05-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300476</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300476</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Is high-resolution spectral domain optical coherence tomography reliable in nystagmus?]]></dc:title>
<prism:publicationDate>2011-09-27</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjo.2010.201970v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjo.2010.201970v1?rss=1</link>
<description><![CDATA[ <p>We thank Drs Raizada and Al Sabti<cross-ref type="bib" refid="b1">1</cross-ref> for their interest in our article &lsquo;Enhanced internal search for iatrogenic retinal breaks in 20-gauge macular surgery&rsquo;<cross-ref type="bib" refid="b2">2</cross-ref> and for their useful comments.</p> <p>We are aware that most vitreoretinal surgeons currently employ wide-field viewing systems and peripheral indentation during their search for retinal breaks at the end of surgery. The existing literature on this subject, however, often mentions indirect funduscopy or does not specify search methods. And from personal communications we still encounter practices of search using indirect ophthalmoscopy, confinement of search to sclerotomy sites or confinement of search only to cases where a posterior vitreous detachment is induced. A recent large series focusing on break incidence in 20-gauge pars plana vitrectomy also found a high number of breaks.<cross-ref type="bib" refid="b3">3</cross-ref> We hope that all this attention will eradicate sloppy search practices by vitreoretinal surgeons.</p> <p>Drs Raizada and Al...]]></description>
<dc:creator><![CDATA[Tan, H. S., Lesnik Oberstein, S. Y., Mura, M., de Smet, M. D.]]></dc:creator>
<dc:date>2011-02-04T02:27:57-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjo.2010.201970</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjo.2010.201970</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2011-02-04</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/bjo.2010.199844v1?rss=1">
<title><![CDATA[Endoscope assisted enhanced internal search for iatrogenic retinal breaks in 20-gauge macular surgery]]></title>
<link>http://bjo.bmj.com/cgi/content/short/bjo.2010.199844v1?rss=1</link>
<description><![CDATA[ <p>We read with interest the article by Tan <I>et al</I>.<cross-ref type="bib" refid="b1">1</cross-ref> We congratulate the authors for emphasising the need for meticulous examination of the peripheral retina to look for retinal breaks after pars plana vitrectomy (PPV). We would like to add some comments to augment this fine study.</p> <p><l type="ord"><li><p>We did not completely understand what the authors mean by &lsquo;intensified search strategy&rsquo; and &lsquo;enhanced 360&deg; internal search&rsquo;. Are they proposing any new technique which is different from what is a common practice? It is a common practice to check for peripheral retinal breaks after PPV and we have been doing this in a similar fashion with the help of the Binocular Indirect Ophthalmol Microscope (BIOM) for the last 10&nbsp;years. This is in fact a routine teaching in all surgical retina fellowship programmes.</p> </li><li> <p>The authors reported a very high incidence of retinal breaks. Breaks were seen in 53...]]></description>
<dc:creator><![CDATA[Raizada, S., Al Sabti, K.]]></dc:creator>
<dc:date>2011-01-17T15:02:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/bjo.2010.199844</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjo.2010.199844</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Endoscope assisted enhanced internal search for iatrogenic retinal breaks in 20-gauge macular surgery]]></dc:title>
<prism:publicationDate>2011-01-17</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
</rdf:RDF>
